A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion Of [14C] Fruquintinib
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
This will be an open-label, single-center study to evaluate pharmacokinetics and safety of
HMPL-013 in approximately 6 healthy male subjects receiving a single oral 5mg dose of
HMPL-013 containing approximately 100 microcuries of [14C] HMPL-013. This study will
investigate the absorption, drug biotransformation and mass balance of HMPL-013, seek to
identify the compound's major metabolites and supply information for clinical application.